Tiziana Life Sciences completes patient enrollment for Milciclib, topline data by mid 2019

Tiziana Life Sciences has completed patient enrollment in the ongoing Phase 2a clinical a single-arm, repeated-dose, 6-month duration study of Milciclib for certain patients with unresectable or metastatic HCC, with the topline data from this multi-center trial, being conducted in Italy, Greece and Israel, will be available in the second quarter of 2019.

Read more